EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin By Ogkologos - August 18, 2025 284 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with relapsed or refractory multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR FDA Approves Zanubrutinib for Waldenström’s Macroglobulinemia September 3, 2021 Scientists Link a Single Type of Bacteria to Colorectal Cancer April 19, 2024 Snowboarder Kimmy Fasani Diagnosed with Breast Cancer Nine Months After Son’s... December 11, 2021 Holiday Coping and Enjoying December 17, 2021 Load more HOT NEWS Answers to Your Questions About the COVID-19 Vaccine Pump Up the Volume: “Priming Agents” May Improve Cancer Liquid Biopsies Five-Year Follow-up of Adjuvant Dabrafenib plus Trametinib in Resected Stage III... Inavolisib Plus Palbociclib–Fulvestrant Prolongs PFS in Patients with PIK3CA-mutated, HR-positive, HER2-negative...
